Bristol Myers Squibb : ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

Press/Media: Press / Media

PeriodApr 25 2015

Media coverage

1

Media coverage

  • TitleBristol Myers Squibb : ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outlet4 Traders
    CountryUnited States
    Date4/25/15
    PersonsFred Poordad